AstraZeneca Plc has reached out to a UK biotech, Aptamer Group Ltd, to explore the use of aptamer technology in developing candidate drugs for kidney disease. Specifically, the two companies will explore the feasibility of developing aptamer drug conjugates to deliver therapeutic molecules to the kidney.
